Temperature dependent charge transport mechanisms in carbon sphere/polymer composites

Carbon spheres (CS) with diameters in the range $2 - 10 \mu m$ were prepared via hydrolysis of a sucrose solution at $200^o C,$ and later annealed in $N_2$ at $800^o C.$ The spheres were highly conducting but difficult to process into thin films or pressed pellets. In our previous work, composite samples of CS and the insulating polymer polyethylene oxide (PEO) were prepared and their charge transport was analyzed in the temperature range $80 K < T < 300 K.$ Here, we analyze charge transport in CS coated with a thin polyaniline (PANi) film doped with hydrochloric acid (HCl), in the same temperature range. The goal is to study charge transport in the CS using a conducting polymer (PANi) as a binder and compare with that occurring at CS/PEO. A conductivity maxima was observed in the CS/PEO composite but was absent in CS/PANi. Our data analysis shows that variable range hopping of electrons between polymeric chains in PANi-filled gaps between CS takes on a predominant part in transport through CS/PANi composites, whereas in CS/PEO composites, electrons travel through gaps between CS solely by means of direct tunneling. This difference in transport mechanisms results in different temperature dependences of the conductivity.Comment: 7 pages, 6 figure

Integration of Virtual Reality Procedural Training in a Flight Training Curriculum

As Virtual Reality (VR) technology becomes more affordable, integrating VR training into pilot training programs is becoming a focus of many flight schools and universities. The purpose of this study is to investigate the impact of VR software and supporting devices as a familiarization and procedural trainer for private pilot students. This presentation will introduce the usage of the VR software for procedural training in the new private pilot training program implemented by the Embry-Riddle Aeronautical University’s Daytona Beach Campus Flight Department. In this program, new private pilot students partake in a month-long program to learn basic skills and knowledge to prepare them for their upcoming flight lessons. The presentation will cover: 1) A brief introduction to the Commercial Aviation Augmented Reality Toolkit (CAART) software, 2) An outline of how this software is used in the overall layout of the training course, 3) A description of the equipment used including examples and a display of each of the three types of training delivery methods, 4) A discussion of the research plan currently underway and 5) A synopsis of relevant preliminary data regarding the experiences of participants in relation to usability, presence, satisfaction, and simulator sickness. The presentation will cumulate in a discussion outlining future research plans

Neutron-Capture elements in planetary nebulae: first detections of near-Infrared [Te III] and [Br V] emission lines

We have identified two new near-infrared emission lines in the spectra of planetary nebulae (PNe) arising from heavy elements produced by neutron capture reactions: [Te III] 2.1019 $\mu$m and [Br V] 1.6429 $\mu$m. [Te III] was detected in both NGC 7027 and IC 418, while [Br V] was seen in NGC 7027. The observations were obtained with the medium-resolution spectrograph EMIR on the 10.4m Gran Telescopio Canarias at La Palma, and with the high-resolution spectrograph IGRINS on the 2.7m Harlan J. Smith telescope at McDonald Observatory. New calculations of atomic data for these ions, specifically A-values and collision strengths, are presented and used to derive ionic abundances of Te$^{2+}$ and Br$^{4+}$. We also derive ionic abundances of other neutron-capture elements detected in the near-infrared spectra, and estimate total elemental abundances of Se, Br, Kr, Rb, and Te after correcting for unobserved ions. Comparison of our derived enrichments to theoretical predictions from AGB evolutionary models shows reasonable agreement for solar metallicity progenitor stars of $\sim$2 - 4 M$_{\odot}$. The spectrally-isolated [Br V] 1.6429 $\mu$m line has advantages for determining nebular Br abundances over optical [Br III] emission lines that can be blended with other features. Finally, measurements of Te are of special interest because this element lies beyond the first peak of the s-process, and thus provides new leverage on the abundance pattern of trans-iron species produced by AGB stars.Comment: 9 pages, 1 figure, 4 tables. Accepted for publication in ApJ Letter

Two-Way Quantum Time Transfer: A Method for Daytime Space-Earth Links

Remote clock synchronization is crucial for many classical and quantum network applications. Current state-of-the-art remote clock synchronization techniques achieve femtosecond-scale clock stability utilizing frequency combs, which are supplementary to quantum-networking hardware. Demonstrating an alternative, we synchronize two remote clocks across our freespace testbed using a method called two-way quantum time transfer (QTT). In one second we reach picosecond-scale timing precision under very lossy and noisy channel conditions representative of daytime space-Earth links with commercial off-the-shelf quantum-photon sources and detection equipment. This work demonstrates how QTT is potentially relevant for daytime space-Earth quantum networking and/or providing high-precision secure timing in GPS-denied environments.Comment: arXiv admin note: text overlap with arXiv:2211.0073

Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes

The designation of Burkholderia pseudomallei as a category B select agent has resulted in considerable research funding to develop a protective vaccine. This bacterium also causes a naturally occurring disease (melioidosis), an important cause of death in many countries including Thailand and Australia. In this study, we explored whether a vaccine could be used to provide protection from melioidosis. An economic evaluation based on its use in Thailand indicated that a vaccine could be a cost-effective intervention if used in high-risk populations such as diabetics and those with chronic kidney or lung disease. A literature search of vaccine studies in animal models identified the current candidates, but noted that models failed to take account of the common routes of infection in natural melioidosis and major risk factors for infection, primarily diabetes. This review highlights important areas for future research if biodefence-driven vaccines are to play a role in reducing the global incidence of melioidosis

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update

Hereditary angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1 inhibitor (type 1) and HAE with dysfunctional C1 inhibitor (type 2), by providing guidance on common and important clinical issues, such as: (1) How should HAE be diagnosed? (2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? (3) What are the goals of treatment? (4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast-feeding women? and (5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients

The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.

Hereditary Angioedema (HAE) is a rare and disabling disease for which early diagnosis and effective therapy are critical. This revision and update of the global WAO/EAACI guideline on the diagnosis and management of HAE provides up-to-date guidance for the management of HAE. For this update and revision of the guideline, an international panel of experts reviewed the existing evidence, developed 28 recommendations, and established consensus by an online DELPHI process. The goal of these recommendations and guideline is to help physicians and their patients in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2), by providing guidance on common and important clinical issues, such as: 1) How should HAE be diagnosed? 2) When should HAE patients receive prophylactic on top of on-demand treatment and what treatments should be used? 3) What are the goals of treatment? 4) Should HAE management be different for special HAE patient groups such as children or pregnant/breast feeding women? 5) How should HAE patients monitor their disease activity, impact, and control? It is also the intention of this guideline to help establish global standards for the management of HAE and to encourage and facilitate the use of recommended diagnostics and therapies for all patients

Changes in total body bone mineral density following a common bone health plan with two versions of a unique bone health supplement: a comparative effectiveness research study

<p>Abstract</p> <p>Background</p> <p>The US Surgeon General's Report on Bone Health suggests America's bone-health is in jeopardy and issued a "call to action" to develop bone-health plans that: (1) improve nutrition, (2) increase health literacy and, (3) increase physical activity. This study is a response to this call to action.</p> <p>Methods</p> <p>After signing an informed consent, 158 adults agreed to follow an open-label bone-health plan for six months after taking a DXA test of bone density, a 43-chemistry blood test panel and a quality of life inventory (AlgaeCal 1). Two weeks after the last subject completed, a second group of 58 was enrolled and followed the identical plan, but with a different bone-health supplement (AlgaeCal 2).</p> <p>Results</p> <p>There were no significant differences between the two groups in baseline bone mineral density (BMD) or in variables related to BMD (age, sex, weight, percent body fat, fat mass, or fat-free mass). In both groups, no significant differences in BMD or related variables were found between volunteers and non-volunteers or between those who completed per protocol and those who were lost to attrition.</p> <p>Both groups experienced a significant positive mean annualized percent change (MAPC) in BMD compared to expectation [AlgaeCal 1: 1.15%, <it>p </it>= 0.001; AlgaeCal 2: 2.79%, <it>p </it>= 0.001]. Both groups experienced a positive MAPC compared to baseline, but only AlgaeCal 2 experienced a significant change [AlgaeCal 1: 0.48%, <it>p </it>= 0.14; AlgaeCal 2: 2.18%, <it>p </it>< 0.001]. The MAPC in AlgaeCal 2 was significantly greater than that in AlgaeCal 1 (<it>p </it>= 0.005). The MAPC contrast between compliant and partially compliant subjects was significant for both plans (<it>p </it>= 0.001 and <it>p </it>= 0.003 respectively). No clinically significant changes in a 43-panel blood chemistry test were found nor were there any changes in self-reported quality of life in either group.</p> <p>Conclusions</p> <p>Following The Plan for six months with either version of the bone health supplement was associated with significant increases in BMD as compared to expected and, in AlgaeCal 2, the increase from baseline was significantly greater than the increase from baseline in AlgaeCal 1. Increased compliance was associated with greater increases in BMD in both groups. No adverse effects were reported in either group.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov <a href="http://www.clinicaltrials.gov/ct2/show/NCT01114685">NCT01114685</a></p

Global Retinoblastoma Presentation and Analysis by National Income Level.

Importance: Early diagnosis of retinoblastoma, the most common intraocular cancer, can save both a child's life and vision. However, anecdotal evidence suggests that many children across the world are diagnosed late. To our knowledge, the clinical presentation of retinoblastoma has never been assessed on a global scale. Objectives: To report the retinoblastoma stage at diagnosis in patients across the world during a single year, to investigate associations between clinical variables and national income level, and to investigate risk factors for advanced disease at diagnosis. Design, Setting, and Participants: A total of 278 retinoblastoma treatment centers were recruited from June 2017 through December 2018 to participate in a cross-sectional analysis of treatment-naive patients with retinoblastoma who were diagnosed in 2017. Main Outcomes and Measures: Age at presentation, proportion of familial history of retinoblastoma, and tumor stage and metastasis. Results: The cohort included 4351 new patients from 153 countries; the median age at diagnosis was 30.5 (interquartile range, 18.3-45.9) months, and 1976 patients (45.4%) were female. Most patients (n = 3685 [84.7%]) were from low- and middle-income countries (LMICs). Globally, the most common indication for referral was leukocoria (n = 2638 [62.8%]), followed by strabismus (n = 429 [10.2%]) and proptosis (n = 309 [7.4%]). Patients from high-income countries (HICs) were diagnosed at a median age of 14.1 months, with 656 of 666 (98.5%) patients having intraocular retinoblastoma and 2 (0.3%) having metastasis. Patients from low-income countries were diagnosed at a median age of 30.5 months, with 256 of 521 (49.1%) having extraocular retinoblastoma and 94 of 498 (18.9%) having metastasis. Lower national income level was associated with older presentation age, higher proportion of locally advanced disease and distant metastasis, and smaller proportion of familial history of retinoblastoma. Advanced disease at diagnosis was more common in LMICs even after adjusting for age (odds ratio for low-income countries vs upper-middle-income countries and HICs, 17.92 [95% CI, 12.94-24.80], and for lower-middle-income countries vs upper-middle-income countries and HICs, 5.74 [95% CI, 4.30-7.68]). Conclusions and Relevance: This study is estimated to have included more than half of all new retinoblastoma cases worldwide in 2017. Children from LMICs, where the main global retinoblastoma burden lies, presented at an older age with more advanced disease and demonstrated a smaller proportion of familial history of retinoblastoma, likely because many do not reach a childbearing age. Given that retinoblastoma is curable, these data are concerning and mandate intervention at national and international levels. Further studies are needed to investigate factors, other than age at presentation, that may be associated with advanced disease in LMICs